Evidence map›Paper›PMID 37291903›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023

Clinical course of multiple sclerosis and patient experiences during breast cancer treatment.

Alyssa N Nylander, Jessica Singh, Shane Poole, Annika Anderson, Ruth Ann Marrie, Hope Rugo, Riley Bove

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Alyssa N NylanderWeill Institute for Neurosciences, University of California San Francisco (UCSF), San Francisco, CA, USA.ORCID 0000-0002-1976-3847
Jessica SinghWeill Institute for Neurosciences, University of California San Francisco (UCSF), San Francisco, CA, USA.
Shane PooleWeill Institute for Neurosciences, University of California San Francisco (UCSF), San Francisco, CA, USA.
Annika AndersonWeill Institute for Neurosciences, University of California San Francisco (UCSF), San Francisco, CA, USA.
Ruth Ann MarrieMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.ORCID 0000-0002-1855-5595
Hope RugoHelen Diller Family Comprehensive Cancer Center, University of California San Francisco (UCSF), San Francisco, CA, USA.
Riley BoveWeill Institute for Neurosciences, University of California San Francisco (UCSF), San Francisco, CA, USA.ORCID 0000-0002-2034-8800
University of California, San Francisco · USUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver one-third of multiple sclerosis (MS) patients are post-menopausal women, the primary demographic affected by breast cancer. After breast cancer diagnosis, there is little information about patients' clinical experiences with both diseases.

objectiveUtilize a case series of MS patients diagnosed with breast cancer to characterize oncologic and MS trajectories, and generate novel insights about clinical considerations using qualitative analysis.

methodsA single-center retrospective review was performed on medical record data of patients with MS and breast cancer. Thematic analysis was used to characterize experiences with the concurrent diagnoses.

resultsFor the 43 patients identified, mean age was 56.7 years at cancer diagnosis and MS duration was 16.5 years. Approximately half were treated with MS disease modifying therapy at cancer diagnosis, and half of these subsequently discontinued or changed therapy. Altogether 14% experienced MS relapse(s) during follow-up (with 2 relapses in the first 2 years), with mean annualized relapse rate of 0.03. Cohort Expanded Disability Status Scale (EDSS) scores remained stable during follow-up. Qualitative insights unique to this population were identified regarding immunosuppression use and neurologic symptoms.

conclusionsMS relapses were infrequent, and there was modest progression during breast cancer treatment. Oncologic outcomes were comparable to non-MS patients with similarly staged cancer.

Indexed as

Breast NeoplasmsMultiple SclerosisDisease ProgressionFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPatient Outcome Assessmentbreast neoplasmscomorbidityimmunosuppression therapyMultiple sclerosisprognosisqualitative researchretrospective studies

Identifiers

PMID37291903
PMCPMC10338705
OpenAlexW4379966936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.